Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 95

Sort by

Sort Order Select

Journal Articles

Mim8 prophylaxis in adults and adolescents with hemophilia A: 52-week efficacy and safety outcomes from the phase 3 FRONTIER2 study

Steven Lentz, Aby Abraham, Cihan Ay, Anthony Chan, Víctor Jiménez-Yuste, Johannes Oldenburg, Maria Elisa Mancuso, Johnny Mahlangu, Tadashi Matsushita, Lize van Vulpen, Renchi Yang, Amalie Rhode Høgh Nielsen, Ilgiz Rakhmatullin, Pratima Chowdary

Blood (2025) 146 (Supplement 1): 537.

https://doi.org/10.1182/blood-2025-537

Published: 2025

Journal Articles

Impact of treatment with fostamatinib on coagulation profile of patients with immune thrombocytopenia

Ana Mendoza Martínez, Elena Monzon Manzano, Paula Acuña, Elena G Arias-Salgado, Jose Manuel Martín de Bustamante Gonzalez-Iglesias, Maria Isabel Rivas Pollmar, Eduardo Garcia Perez, Monica Martin Salces, Mar Gutierrez Alvariño, Víctor Jiménez-Yuste, Waleed Ghanima, Lamya Garabet, Nora Butta, María Teresa Alvarez-Román

Blood (2025) 146 (Supplement 1): 1242.

https://doi.org/10.1182/blood-2025-1242

Published: 2025

Journal Articles

NXT007 prophylaxis in people with hemophilia A with or without FVIII inhibitors: A global Phase I/II multiple-ascending-dose study

Maria Elisa Mancuso, Davide Matino, Dan Hart, Francisco-Jose Lopez-Jaime, Christophe Schmitt, Amy Shapiro, Giuliana Ventriglia, Anna Kiialainen, Laura Young, Olivier Catalani, Mark Belletrutti, Tom Chu, Jerzy Windyga, Víctor Jiménez-Yuste, Michaela Lehle, Janice Staber

Blood (2025) 146 (Supplement 1): 302.

https://doi.org/10.1182/blood-2025-302

Published: 2025

Journal Articles

Long term effect of marstacimab prophylaxis in hemophilia Α and Β on target joints: Results from BASIS and OLE studies

Víctor Jiménez-Yuste, Johnny Mahlangu, Hae Kyung Kim, Travis Gould, Eugeny Mefyod, Pengling Sun, Bryan McComb, Carrie Turich Taylor, Andrew Palladino

Blood (2025) 146 (Supplement 1): 4844.

https://doi.org/10.1182/blood-2025-4844

Published: 2025

Journal Articles

Pharmacodynamic biomarkers in people with hemophilia A receiving multiple ascending doses of NXT007

Anna Kiialainen, Christophe Schmitt, Davide Matino, Janice Staber, Maria Elisa Mancuso, Víctor Jiménez-Yuste, Jerzy Windyga, Amy Shapiro, Matthew Locke, Dan Hart

Blood (2025) 146 (Supplement 1): 4841.

https://doi.org/10.1182/blood-2025-4841

Published: 2025

Journal Articles

Evolution of joint health and physical activity in people with hemophilia A without factor VIII inhibitors switching to emicizumab prophylaxis: A second interim analysis of the BEYOND ABR study

Rebecca Kruse-Jarres, Giancarlo Castaman, Matteo Nicola Dario Di Minno, David Stephensen, Sébastien Lobet, Simona Barlera, Cristian Brocchieri, Víctor Jiménez-Yuste

Blood (2025) 146 (Supplement 1): 1285.

https://doi.org/10.1182/blood-2025-1285

Published: 2025

Journal Articles

Patients with immune thrombocytopenia and antiplatelet antibodies show increased platelet activation and desialylation

Elena Monzon Manzano, Paula Acuña, María Teresa Alvarez-Román, Elena G Arias-Salgado, Ana Mendoza Martínez, Rick Kapur, Leendert Porcelijn, Monica Martin Salces, Maria Isabel Rivas Pollmar, Víctor Jiménez-Yuste, Nora Butta

Blood (2025) 146 (Supplement 1): 4792.

https://doi.org/10.1182/blood-2025-4792

Published: 2025

Journal Articles

Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial

Davide Matino, Andrew Palladino, Carrie Turich Taylor, Eunhee Hwang, Sangeeta Raje, Satyaprakash Nayak, Regina McDonald, Suchitra S. Acharya, Johnny Mahlangu, Victor Jiménez-Yuste, Nirmalkumar Choraria, Renchi Yang, Chi-kong Li, Murtadha Al-Khabori, Yasser Wali, Javier Morales Adrián, Young-Shil Park, O. Bülent Zülfikar, John Teeter

Blood (2025) 146 (14): 1654–1663.

https://doi.org/10.1182/blood.2024027468

Published: 2025

Includes: Supplemental data

Journal Articles

B-Cell Distribution in Immune Thrombocytopenia and Its Relation to Ageing

Elena Monzón Manzano, María Teresa Alvarez-Román, Lucía del Pino, Paula Acuña, Rick Kapur, Leendert Porcelijn, Monica Martin Salces, Elena G Arias-Salgado, Maria Isabel Rivas Pollmar, Ana Mendoza, Eduardo López Granados, Victor Jimenez Yuste, Nora Butta

Blood (2024) 144 (Supplement 1): 2569.

https://doi.org/10.1182/blood-2024-202993

Published: 2024

Journal Articles

Pain Reduction Following Treatment of Bleeding Episodes with Eptacog Beta in Adults and Adolescents with Hemophilia A or B Complicated By Inhibitors

Tyler W. Buckner, Craig Kessler, Giancarlo Castaman, Cédric Hermans, Victor Jimenez-Yuste, Johnny Mahlangu, Wolfgang A. Miesbach, Johannes Oldenburg, Michael Recht, Leonard A. Valentino, Allison P Wheeler, Steven W. Pipe

Blood (2024) 144 (Supplement 1): 3972.

https://doi.org/10.1182/blood-2024-194935

Published: 2024

Journal Articles

Safety and Efficacy of Mim8 Prophylaxis Administered Once Every Two Weeks for Patients with Hemophilia A with or without Inhibitors: Interim Analysis of the FRONTIER4 Open-Label Extension Study

Tadashi Matsushita, Pratima Chowdary, Atanas Mitkov Banchev, Kaan Kavakli, Johanna A. Kremer Hovinga, Jerzy Windyga, Víctor Jiménez-Yuste, Julien Bovet, Llenalia María García Fernández, Guy Young

Blood (2024) 144 (Supplement 1): 718.

https://doi.org/10.1182/blood-2024-198617

Published: 2024

Journal Articles

Anticoagulant Therapy in Patients with Severe Factor XI Deficiency

Mar Gutierrez Alvarino, Maria Isabel Rivas Pollmar, Nora Butta, Eduardo Garcia Perez, Victor Jimenez Yuste, Monica Martin Salces, Jose martin De Bustamante, maria Jesus Blanco Bañares, Mikel fernandez Artazkoz, Matias gabriel Facal, Patricia Gonzalez Marugan, Maria Asunción Hernandez Arriaza, María Teresa Álvarez Román

Blood (2024) 144 (Supplement 1): 5563.

https://doi.org/10.1182/blood-2024-204709

Published: 2024

Journal Articles

Monitoring the Hemostatic Effects of Inhibitory Alloantibodies in Von Willebrand Disease Using Global Coagulation Assays

Elena G Arias-Salgado, Nora Butta, Paula Acuña, Elena Monzón Manzano, Monica Martin Salces, Maria Isabel Rivas Pollmar, Rick Kapur, Víctor Jiménez-Yuste, María Teresa Alvarez-Román

Blood (2024) 144 (Supplement 1): 5470.

https://doi.org/10.1182/blood-2024-210405

Published: 2024

Journal Articles

Concizumab As a Possible Treatment for Bleeding Disordersof Unknown Cause

Paula Acuña, Elena Monzón Manzano, María Teresa Alvarez-Román, Elena G Arias-Salgado, Eduardo Garcia Perez, Monica Martin Salces, Maria Isabel Rivas Pollmar, Rick Kapur, Victor Jimenez Yuste, Nora Butta

Blood (2024) 144 (Supplement 1): 3977.

https://doi.org/10.1182/blood-2024-200067

Published: 2024

Journal Articles

Physical and Psychological Burden on People with Hemophilia: Global Real-World Data

Giancarlo Castaman, Cléa Percier, Naveen Shridhar, Neil Reynolds, Olivera Rajkovic-Hooley, Thom Dewar, Víctor Jiménez-Yuste

Blood (2024) 144 (Supplement 1): 2318.

https://doi.org/10.1182/blood-2024-200033

Published: 2024

Journal Articles

Burden of Treatment on People with Hemophilia: Global Real-World Data

Víctor Jiménez-Yuste, Cléa Percier, Naveen Shridhar, Neil Reynolds, Olivera Rajkovic-Hooley, Thom Dewar, Giancarlo Castaman

Blood (2024) 144 (Supplement 1): 5077.

https://doi.org/10.1182/blood-2024-200008

Published: 2024

Journal Articles

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

Steven W. Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Sonia Deb, Markus Niggli, Tiffany Chang, Michaela Lehle, Karin Fijnvandraat

Blood (2024) 143 (14): 1355–1364.

https://doi.org/10.1182/blood.2023021832

Published: 2024

Includes: Supplemental data

Journal Articles

Monitoring of Hemostatic Status and Treatment Response in Von Willebrand Disease Using a Microchip Flow Chamber Assay

Elena G Arias-Salgado, Paula Acuña, Elena Monzón Manzano, Monica Martin Salces, Maria Isabel Rivas Pollmar, Pilar Lopez Gotor, Nora Butta, Cedric R. Hermans, Víctor Jiménez-Yuste, Maria Teresa Álvarez-Roman

Blood (2023) 142 (Supplement 1): 5396.

https://doi.org/10.1182/blood-2023-187360

Published: 2023

Journal Articles

Design of an Observational Study (PROVE) to Assess the Long-Term Effects of Prophylaxis with Simoctocog Alfa or Emicizumab on Joint and Bone Health in Hemophilia a Patients

Robert Klamroth, Robert F Sidonio, Jr., Yesim Dargaud, Víctor Jiménez-Yuste, Rolf Ljung, Guy Young, Pratima Chowdary

Blood (2023) 142 (Supplement 1): 1255.

https://doi.org/10.1182/blood-2023-181725

Published: 2023

Journal Articles

Emicizumab Prophylaxis in People with Moderate or Mild Hemophilia A Aged ≥40 Years, with and without Comorbidities - Findings from the Phase III HAVEN 6 Study

Víctor Jiménez-Yuste, Eunice Tzeng, Elise Lim, Giuliana Ventriglia, Amy D. Shapiro, Johannes Oldenburg, Johnny Mahlangu

Blood (2023) 142 (Supplement 1): 5495.

https://doi.org/10.1182/blood-2023-173016

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Mim8 prophylaxis in adults and adolescents with hemophilia A: 52-week efficacy and safety outcomes from the phase 3 FRONTIER2 study

Impact of treatment with fostamatinib on coagulation profile of patients with immune thrombocytopenia

NXT007 prophylaxis in people with hemophilia A with or without FVIII inhibitors: A global Phase I/II multiple-ascending-dose study

Long term effect of marstacimab prophylaxis in hemophilia Α and Β on target joints: Results from BASIS and OLE studies

Pharmacodynamic biomarkers in people with hemophilia A receiving multiple ascending doses of NXT007

Evolution of joint health and physical activity in people with hemophilia A without factor VIII inhibitors switching to emicizumab prophylaxis: A second interim analysis of the BEYOND ABR study

Patients with immune thrombocytopenia and antiplatelet antibodies show increased platelet activation and desialylation

Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial

B-Cell Distribution in Immune Thrombocytopenia and Its Relation to Ageing

Pain Reduction Following Treatment of Bleeding Episodes with Eptacog Beta in Adults and Adolescents with Hemophilia A or B Complicated By Inhibitors

Safety and Efficacy of Mim8 Prophylaxis Administered Once Every Two Weeks for Patients with Hemophilia A with or without Inhibitors: Interim Analysis of the FRONTIER4 Open-Label Extension Study

Anticoagulant Therapy in Patients with Severe Factor XI Deficiency

Monitoring the Hemostatic Effects of Inhibitory Alloantibodies in Von Willebrand Disease Using Global Coagulation Assays

Concizumab As a Possible Treatment for Bleeding Disordersof Unknown Cause

Physical and Psychological Burden on People with Hemophilia: Global Real-World Data

Burden of Treatment on People with Hemophilia: Global Real-World Data

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

Monitoring of Hemostatic Status and Treatment Response in Von Willebrand Disease Using a Microchip Flow Chamber Assay

Design of an Observational Study (PROVE) to Assess the Long-Term Effects of Prophylaxis with Simoctocog Alfa or Emicizumab on Joint and Bone Health in Hemophilia a Patients

Emicizumab Prophylaxis in People with Moderate or Mild Hemophilia A Aged ≥40 Years, with and without Comorbidities - Findings from the Phase III HAVEN 6 Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only